

## ASH 2013: Highlights zu Bendamustin und liposomalem Cytarabin

**Vom 7. bis 10. Dezember findet die 55. Jahrestagung der American Society of Hematology (ASH) 2013 in New Orleans statt. Ein spannendes und umfangreiches Programm steht uns bevor. Erwartet werden zahlreiche Teilnehmer aus der ganzen Welt.**

Auf der Webseite <http://www.hematology.org/meetings/annual-meeting/> finden Sie Informationen, die Ihre Kongressplanung erleichtern können.

### **Highlights zu Bendamustin:**

#### **Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM)**

Poster-Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I

Samstag, 7. Dezember 5:30 PM-7:30 PM

Raum: Hall G (Ernest N. Morial Convention Center)

Präsentation: M.-V. Mateos

Poster 2155

#### **Response To 1st-Line Treatment With BR Or R-CHOP In Patients With Indolent Non-Hodgkin's Lymphoma: First Outcome Data From The German Prospective TLN Registry**

Poster-Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster II

Sonntag, 8. Dezember 6:30 PM-8:30 PM

Raum: Hall G (Ernest N. Morial Convention Center)

Präsentation: W. Knauf

Poster 3036

#### **Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase 1b Galton Trial (GAO4779g)**

Oral Session: 642. CLL: Therapy, excluding Transplantation: Chemoimmunotherapy Clinical Trials

Montag, 9. Dezember 2:45 PM-4:15 PM

Raum: 220-222 (Ernest N. Morial Convention Center)

Präsentation: J.R. Brown 2:45 PM

Abstract 523

#### **Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study**

Oral Session: 642. CLL: Therapy, excluding Transplantation: Chemoimmunotherapy Clinical Trials

Montag, 9. Dezember 2:45 PM-4:15 PM

Raum: 220-222 (Ernest N. Morial Convention Center)

Präsentation: J.R. Brown 3:15 PM

Abstract 525

**Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG)**

Oral Session: 642. CLL: Therapy, excluding Transplantation: Chemoimmunotherapy Clinical Trials

Montag, 9. Dezember 2:45 PM-4:15 PM

Raum: 220-222 (Ernest N. Morial Convention Center)

Präsentation: B. Eichhorst 3:30 PM

Abstract 526

**Response To 1st-Line Treatment With BR Or FCR In Patients With Chronic Lymphocytic Leukaemia: First Outcome Data From The German Prospective TLN Registry**

Poster-Session: 642. CLL: Therapy, excluding Transplantation: Poster III

Montag, 9. Dezember 6:00 PM-8:00 PM

Raum: Hall E (Ernest N. Morial Convention Center)

Präsentation: W. Knauf

Poster 4181

**Safety and Efficacy Of Bendamustine In Patients With Aggressive Non-Hodgkin Lymphomas (NHL)**

Poster-Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III

Montag, 9. Dezember 6:00 PM-8:00 PM

Hall G (Ernest N. Morial Convention Center)

Präsentation: J. Hammersen

Poster 4371

**Highlights zu DepoCyte:**

**Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte®) In Adult Acute Lymphoblastic Leukemia (ALL)**

Poster-Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III

Montag, 9. Dezember 6:00 PM-8:00 PM

Raum: Hall E (Ernest N. Morial Convention Center)

Präsentation: R. Bassan

Poster 3901

**Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification**

Poster-Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III

Montag, 9. Dezember 6:00 PM-8:00 PM

Raum: Hall G (Ernest N. Morial Convention Center)

Präsentation: M.B. Ventre

Poster 4365

**Dose-Dense Chemoimmunotherapy and Early Central Nervous System Prophylaxis For High-Risk Diffuse Large B-Cell Lymphoma. -Preliminary Results From a Nordic Phase II Study**

Oral Session: 624. Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Aggressive Lymphomas

Dienstag, 10. Dezember 7:30 AM-9:00 AM

Raum: La Nouvelle Ballroom AB (Ernest N. Morial Convention Center)

Präsentation: S. Leppa 8:00 AM

Abstract 849